Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Significant Growth in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 66,300 shares, an increase of 247.1% from the February 28th total of 19,100 shares. Based on an average daily trading volume, of 4,400,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.9% of the shares of the stock are sold short.

Hedge Funds Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Grant Private Wealth Management Inc acquired a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,193 shares of the company’s stock, valued at approximately $25,000. Grant Private Wealth Management Inc owned 1.00% of Helius Medical Technologies as of its most recent SEC filing. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Stock Performance

Shares of HSDT traded up $0.01 during trading hours on Thursday, reaching $0.41. The stock had a trading volume of 6,967 shares, compared to its average volume of 1,399,660. The stock has a market capitalization of $1.52 million, a PE ratio of -0.07 and a beta of 1.62. Helius Medical Technologies has a 12 month low of $0.37 and a 12 month high of $7.19. The company’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.59.

Helius Medical Technologies (NASDAQ:HSDT) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.09). Helius Medical Technologies had a negative net margin of 1,764.74% and a negative return on equity of 244.82%. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.10 million.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.